Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

COSCIENS Biopharma (CSCI)announced initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed ...

Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the ongoing ...

“Our Phase 2a trial incorporates digital health technologies to measure the effect of VENT-02 on symptoms and a comprehensive set of biomarkers that map inflammation to disease activit ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data ...

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

Longeveron Inc. announced positive results from its Phase 2a CLEAR MIND clinical trial of laromestrocel (Lomecel-B™), a cellular therapy for mild Alzheimer's disease, published in Nature Medicine.